SEC Company Response from First Tracks Biotherapeutics, (TRAX) — May 8, 2026
First Tracks Biotherapeutics, Inc.
Date: May 8, 2026 · CIK: 0002091349 · Accession: 0000950142-26-001339
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295719
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Alan Campbell Division of Corporation Finance Office of Life Sciences First Tracks Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-295719)
Dear Mr. Campbell:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-1 (the "S-1") relating to the registration of 10,497,054 shares of the common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. (the "Company"), be accelerated to May 12, 2026 at 4:00 p.m. E.D.T. or as soon thereafter as may be practicable, or at such other time as the Company or its outside counsel, Paul, Weiss, Rifkind, Wharton & Garrison LLP, may orally request via telephone call that the S-1 be declared effective.
We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Christodoulos Kaoutzanis of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3445.
*****
Very truly yours,
By:
/s/ Daniel Faga
Show Raw Text
CORRESP 1 filename1.htm FIRST TRACKS BIOTHERAPEUTICS, INC. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 May 8, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Division of Corporation Finance Office of Life Sciences First Tracks Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-295719) Dear Mr. Campbell: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-1 (the "S-1") relating to the registration of 10,497,054 shares of the common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. (the "Company"), be accelerated to May 12, 2026 at 4:00 p.m. E.D.T. or as soon thereafter as may be practicable, or at such other time as the Company or its outside counsel, Paul, Weiss, Rifkind, Wharton & Garrison LLP, may orally request via telephone call that the S-1 be declared effective. We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Christodoulos Kaoutzanis of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3445. ***** Very truly yours, By: /s/ Daniel Faga Name: Daniel Faga Title: President and Chief Executive Officer